Why Novo Nordisk Stock Fell Even After Wegovy Pill Hit 3 Million Prescriptions

The Wegovy pill is still dominating the GLP-1 pill market

It has remained a top choice among Americans trying to lose weight even after the launch of Foundayo, Eli Lilly’s GLP-1 pill.

80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case?

Key PointsNovo Nordisk has reported strong initial sales for the pill-based version of its GLP-1 weight loss drug, Wegovy.Sales do not appear to be coming at the expense of Novo's previously released injectable Wegovy products.This could lead to better-than-expected results in the coming quarters even as competition heats up.10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO), previously the early mover in the GLP-1 weight loss…

Why Novo Nordisk Stock Fell Even After Wegovy Pill Hit 3 Million Prescriptions

Novo Nordisk shares plunged over 4% despite Wegovy pills surpassing 3 million U.S. prescriptions, as investors worried strong demand may not translate into profits amid fierce competition from Eli Lilly and AstraZeneca, ongoing U.S. pricing pressure, and concerns about patients remaining on lower-priced doses. The post Why Novo Nordisk Stock Fell Even After Wegovy Pill Hit 3 Million Prescriptions appeared first on TechStock².

Wegovy pill prescriptions hit a milestone

PLAINSBORO, N.J. – Novo Nordisk reported that Wegovy (semaglutide) 25 mg tablets have topped three million U.S. prescriptions in just over five months, making the oral version one of the strongest pharmaceutical launches by volume on record. That milestone equates to roughly one prescription filled every five seconds since the drug’s January 2026 debut.Uptake has been rapid: Wegovy tablets reached their first one million prescriptions within 12 …